Trial Profile

A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary)
Indications Myeloproliferative disorders; Splenomegaly; Venous thrombosis
Focus Therapeutic Use
Acronyms SVT-RUXO

Most Recent Events

13 Dec 2022 Results assessing long-term follow up (FU) of the SVT-RUXO study after a median of 104 months, range 6.2-9.8y, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
06 Nov 2019 Final long term follow up data results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
08 Dec 2015 Long term follow-up results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com